ALK and non-small cell lung carcinoma: Currently, the availability and funding of NGS for standard diagnostic evaluation remain poorly described,7 and expansion of molecular testing beyond EGFR, ALK, and ROS1 for patients with NSCLC persists an unsatisfied challenge in several countries and community settings.8